Max Seidensticker1,2, Maciej Powerski3, Ricarda Seidensticker3,4, Robert Damm3, Konrad Mohnike3,4, Benjamin Garlipp5, Maurice Klopffleisch3, Holger Amthauer3,4, Jens Ricke3,4, Maciej Pech3,4. 1. Klinik für Radiologie und Nuklearmedizin, Universitätsklinik Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. max.seidensticker@med.ovgu.de. 2. International School of Image-Guided Interventions, Deutsche Akademie für Mikrotherapie, Magdeburg, Germany. max.seidensticker@med.ovgu.de. 3. Klinik für Radiologie und Nuklearmedizin, Universitätsklinik Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. 4. International School of Image-Guided Interventions, Deutsche Akademie für Mikrotherapie, Magdeburg, Germany. 5. Klinik für Allgemein-Viszeral- und Gefäßchirurgie, Universitätsklinik Magdeburg, Magdeburg, Germany.
Abstract
BACKGROUND: To evaluate the course of pro- and anti-inflammatory cytokines after 90Y-radioembolization (RE) of liver malignancies and to identify prognosticators for liver-related adverse events and survival. METHODS: In 34 consecutive patients with secondary or primary liver tumors scheduled for RE, the following cytokines were measured prior to and 2 h, 3 days, and 6 weeks after RE: interleukin (IL) -1, IL-2, IL-4, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), and interferon-γ. Liver function impairment was defined as an elevation of liver-related laboratory values as graded by CTCAE ≥ 2 and/or serum bilirubin ≥30 µmol/l and/or development of ascites at 6-week follow-up. RESULTS: Significant changes over time were seen in IL-1 (increase from 0.4 pg/ml (±0.7) at baseline to 1.1 pg/ml (±1.4) 3 days after RE (p = 0.02)), and in IL-6 (increase from 16.8 pg/ml (±21.8) at baseline to 54.6 pg/ml (±78.2) 3 days after RE (p = 0.003)). Baseline values of IL-6 and IL-8 were independently associated with liver function impairment at follow-up as well as decreased survival with an optimal cutoff at 6.53 and 60.8 pg/ml, respectively. CONCLUSION: Expected changes in pro- and anti-inflammatory cytokines after RE were shown. Furthermore, baseline values of IL-6 and IL-8 were associated with later liver dysfunction and survival. We hypothesize that these biomarkers are potential prognosticators and might help in patient selection for RE.
BACKGROUND: To evaluate the course of pro- and anti-inflammatory cytokines after 90Y-radioembolization (RE) of liver malignancies and to identify prognosticators for liver-related adverse events and survival. METHODS: In 34 consecutive patients with secondary or primary liver tumors scheduled for RE, the following cytokines were measured prior to and 2 h, 3 days, and 6 weeks after RE: interleukin (IL) -1, IL-2, IL-4, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), and interferon-γ. Liver function impairment was defined as an elevation of liver-related laboratory values as graded by CTCAE ≥ 2 and/or serum bilirubin ≥30 µmol/l and/or development of ascites at 6-week follow-up. RESULTS: Significant changes over time were seen in IL-1 (increase from 0.4 pg/ml (±0.7) at baseline to 1.1 pg/ml (±1.4) 3 days after RE (p = 0.02)), and in IL-6 (increase from 16.8 pg/ml (±21.8) at baseline to 54.6 pg/ml (±78.2) 3 days after RE (p = 0.003)). Baseline values of IL-6 and IL-8 were independently associated with liver function impairment at follow-up as well as decreased survival with an optimal cutoff at 6.53 and 60.8 pg/ml, respectively. CONCLUSION: Expected changes in pro- and anti-inflammatory cytokines after RE were shown. Furthermore, baseline values of IL-6 and IL-8 were associated with later liver dysfunction and survival. We hypothesize that these biomarkers are potential prognosticators and might help in patient selection for RE.
Authors: Joseph P Erinjeri; Gabriel C Fine; Gosse J Adema; Muneeb Ahmed; Julius Chapiro; Martijn den Brok; Rafael Duran; Stephen J Hunt; D Thor Johnson; Jens Ricke; Daniel Y Sze; Beau Bosko Toskich; Bradford J Wood; David Woodrum; S Nahum Goldberg Journal: Radiology Date: 2019-04-23 Impact factor: 11.105
Authors: Osman Öcal; Juozas Kupčinskas; Egidijus Morkunas; Holger Amthauer; Kerstin Schütte; Peter Malfertheiner; Heinz Josef Klümpen; Christian Sengel; Julia Benckert; Ricarda Seidensticker; Bruno Sangro; Moritz Wildgruber; Maciej Pech; Peter Bartenstein; Jens Ricke; Max Seidensticker Journal: EJNMMI Res Date: 2021-06-02 Impact factor: 3.138
Authors: Matthew M Cousins; Theresa P Devasia; Christopher M Maurino; Justin Mikell; Matthew J Schipper; Ravi K Kaza; Theodore S Lawrence; Kyle C Cuneo; Yuni K Dewaraja Journal: J Nucl Med Date: 2021-09-09 Impact factor: 11.082
Authors: Luis E Soria-Jasso; Raquel Cariño-Cortés; Víctor Manuel Muñoz-Pérez; Elizabeth Pérez-Hernández; Nury Pérez-Hernández; Eduardo Fernández-Martínez Journal: Int J Mol Sci Date: 2019-09-22 Impact factor: 5.923
Authors: Osman Öcal; Kerstin Schütte; Juozas Kupčinskas; Egidijus Morkunas; Gabija Jurkeviciute; Enrico N de Toni; Najib Ben Khaled; Thomas Berg; Peter Malfertheiner; Heinz Josef Klümpen; Christian Sengel; Bristi Basu; Juan W Valle; Julia Benckert; Antonio Gasbarrini; Daniel Palmer; Ricarda Seidensticker; Moritz Wildgruber; Bruno Sangro; Maciej Pech; Jens Ricke; Max Seidensticker Journal: J Cancer Res Clin Oncol Date: 2021-04-14 Impact factor: 4.553